F04726 – Respiratory Virus Trial
We are looking for healthy adults aged 18-49 or 60-84 to help evaluate a potential new vaccine designed to protect against common respiratory viruses. The study involves a single vaccination and includes regular health check-ups and safety monitoring over approximately 12 months. Respiratory viruses such as RSV, human metapneumovirus, and parainfluenza virus are a significant cause of serious illness in older adults. This research could play an important role in helping to protect against them in the future.
Sign up below to see if this study is suitable for you.
Eligibility requirements
- Age: 18-49 or 60-84
- Sex: M & F
- BMI: 18-35
- Weight: Stable and within BMI range at screening
- Medication: All medications taken at the time of enrolment or during the study will be recorded. You cannot have received any non-live vaccine within 14 days or any live vaccine within 30 days prior to study vaccination. You must not have received a licensed RSV vaccine. You must not be taking immunosuppressive medications such as systemic corticosteroids. You cannot have received any blood transfusion or immunoglobulin products within 3 months prior to study vaccination.
- Medical History: Any ongoing illnesses, pre-existing conditions, allergies, and prior significant illnesses will be recorded. To take part in this study you must be in good general health as determined by the study team. You cannot participate if you have a known or suspected impairment of immune function, a history of Guillain-Barré Syndrome, a history of significant allergic reactions, a history of cancer, or any unstable chronic medical condition. You must not have been hospitalised due to a lower respiratory tract illness in the past 12 months. Cannot have a tattoo on the upper arm at the vaccination site which would impair the assessment of the site for any reactions.
- Smoking History: Participants may smoke up to 10 cigarettes per day. You must not have a history of clinically significant drug or alcohol abuse within the past year.
Overnight Stays
- Nil
Outpatient Visits
- Approximately 9 clinic visits plus 2 safety phone calls over 12 months including screening, vaccination day, and follow-up visits at Day 2, Day 8, Day 29, Month 3, Month 6, Month 9, and Month 12.
Payment/Remuneration
- You will be reimbursed $250 for the screening visit and if elligible, $490 for the dosing day, $250 for each visit to the site, $50 per scheduled phone call, and an additional $500 if you complete the study and complete all required activities.
How to apply
To register your interest in this trial, please complete the form below, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.